Fulminant Liver Failure due to Hepatitis B Reactivation During Treatment With Tocilizumab

Tocilizumab is a humanized monoclonal antibody targeting the interleukin-6 receptor that is frequently used for the treatment of refractory rheumatoid arthritis. Since patients with hepatitis B virus (HBV) infection were excluded from pivotal trials, the risk of HBV reactivation with this novel drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Sonneveld, Milan J., Murad, S. Darwish, van der Eijk, A.A., de Man, R.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946203/
https://www.ncbi.nlm.nih.gov/pubmed/32042838
http://dx.doi.org/10.14309/crj.0000000000000243
_version_ 1783485310179475456
author Sonneveld, Milan J.
Murad, S. Darwish
van der Eijk, A.A.
de Man, R.A.
author_facet Sonneveld, Milan J.
Murad, S. Darwish
van der Eijk, A.A.
de Man, R.A.
author_sort Sonneveld, Milan J.
collection PubMed
description Tocilizumab is a humanized monoclonal antibody targeting the interleukin-6 receptor that is frequently used for the treatment of refractory rheumatoid arthritis. Since patients with hepatitis B virus (HBV) infection were excluded from pivotal trials, the risk of HBV reactivation with this novel drug class remains uncertain. We present the first case of tocilizumab-associated HBV reactivation resulting in fulminant hepatic failure and a need for liver transplant. Our findings underscore the need for prophylactic antiviral therapy in patients being treated with novel immunosuppressive agents.
format Online
Article
Text
id pubmed-6946203
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-69462032020-02-10 Fulminant Liver Failure due to Hepatitis B Reactivation During Treatment With Tocilizumab Sonneveld, Milan J. Murad, S. Darwish van der Eijk, A.A. de Man, R.A. ACG Case Rep J Case Report Tocilizumab is a humanized monoclonal antibody targeting the interleukin-6 receptor that is frequently used for the treatment of refractory rheumatoid arthritis. Since patients with hepatitis B virus (HBV) infection were excluded from pivotal trials, the risk of HBV reactivation with this novel drug class remains uncertain. We present the first case of tocilizumab-associated HBV reactivation resulting in fulminant hepatic failure and a need for liver transplant. Our findings underscore the need for prophylactic antiviral therapy in patients being treated with novel immunosuppressive agents. Wolters Kluwer 2019-12-09 /pmc/articles/PMC6946203/ /pubmed/32042838 http://dx.doi.org/10.14309/crj.0000000000000243 Text en © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Case Report
Sonneveld, Milan J.
Murad, S. Darwish
van der Eijk, A.A.
de Man, R.A.
Fulminant Liver Failure due to Hepatitis B Reactivation During Treatment With Tocilizumab
title Fulminant Liver Failure due to Hepatitis B Reactivation During Treatment With Tocilizumab
title_full Fulminant Liver Failure due to Hepatitis B Reactivation During Treatment With Tocilizumab
title_fullStr Fulminant Liver Failure due to Hepatitis B Reactivation During Treatment With Tocilizumab
title_full_unstemmed Fulminant Liver Failure due to Hepatitis B Reactivation During Treatment With Tocilizumab
title_short Fulminant Liver Failure due to Hepatitis B Reactivation During Treatment With Tocilizumab
title_sort fulminant liver failure due to hepatitis b reactivation during treatment with tocilizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946203/
https://www.ncbi.nlm.nih.gov/pubmed/32042838
http://dx.doi.org/10.14309/crj.0000000000000243
work_keys_str_mv AT sonneveldmilanj fulminantliverfailureduetohepatitisbreactivationduringtreatmentwithtocilizumab
AT muradsdarwish fulminantliverfailureduetohepatitisbreactivationduringtreatmentwithtocilizumab
AT vandereijkaa fulminantliverfailureduetohepatitisbreactivationduringtreatmentwithtocilizumab
AT demanra fulminantliverfailureduetohepatitisbreactivationduringtreatmentwithtocilizumab

Ejemplares similares